ABIONYX Pharma S.A.
ABNX.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €5 | €5 | €5 | €1 |
| % Growth | -0.9% | -11.7% | 678.1% | – |
| Cost of Goods Sold | €4 | €4 | €5 | €0 |
| Gross Profit | €1 | €1 | €1 | €0 |
| % Margin | 18.3% | 13.3% | 12.1% | 38.4% |
| R&D Expenses | €3 | €3 | €3 | €6 |
| G&A Expenses | €1 | €1 | €1 | €1 |
| SG&A Expenses | €1 | €1 | €1 | €1 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | €1 | €0 | €1 | €0 |
| Operating Expenses | €5 | €4 | €5 | €6 |
| Operating Income | -€6 | -€3 | -€4 | -€6 |
| % Margin | -121.1% | -73.5% | -78.2% | -881.8% |
| Other Income/Exp. Net | €0 | -€0 | -€0 | €0 |
| Pre-Tax Income | -€5 | -€4 | -€4 | -€6 |
| Tax Expense | -€1 | €0 | -€1 | €0 |
| Net Income | -€4 | -€4 | -€4 | -€6 |
| % Margin | -95.7% | -75.8% | -80.1% | -862.5% |
| EPS | -0.13 | -0.12 | -0.15 | -0.23 |
| % Growth | -8.3% | 20% | 34.8% | – |
| EPS Diluted | -0.13 | -0.12 | -0.15 | -0.23 |
| Weighted Avg Shares Out | 34 | 29 | 28 | 25 |
| Weighted Avg Shares Out Dil | 34 | 29 | 28 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €0 |
| Interest Expense | €0 | €0 | €0 | €0 |
| Depreciation & Amortization | €0 | -€0 | €0 | €0 |
| EBITDA | -€5 | -€5 | -€4 | -€7 |
| % Margin | -107.1% | -104.4% | -76.4% | -1,099% |